232 related articles for article (PubMed ID: 25085657)
1. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.
Ekici H; Rao SD; Sönnerborg A; Ramprasad VL; Gupta R; Neogi U
J Antimicrob Chemother; 2014 Dec; 69(12):3349-55. PubMed ID: 25085657
[TBL] [Abstract][Full Text] [Related]
2. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India.
Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A
Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043
[TBL] [Abstract][Full Text] [Related]
3. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
[TBL] [Abstract][Full Text] [Related]
4. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
5. Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.
Fisher RG; Smith DM; Murrell B; Slabbert R; Kirby BM; Edson C; Cotton MF; Haubrich RH; Kosakovsky Pond SL; Van Zyl GU
J Clin Virol; 2015 Jan; 62():48-53. PubMed ID: 25542470
[TBL] [Abstract][Full Text] [Related]
6. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Rhee SY; Jordan MR; Raizes E; Chua A; Parkin N; Kantor R; Van Zyl GU; Mukui I; Hosseinipour MC; Frenkel LM; Ndembi N; Hamers RL; Rinke de Wit TF; Wallis CL; Gupta RK; Fokam J; Zeh C; Schapiro JM; Carmona S; Katzenstein D; Tang M; Aghokeng AF; De Oliveira T; Wensing AM; Gallant JE; Wainberg MA; Richman DD; Fitzgibbon JE; Schito M; Bertagnolio S; Yang C; Shafer RW
PLoS One; 2015; 10(12):e0145772. PubMed ID: 26717411
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Vela Diagnostics HIV-1 genotyping assay on an automated next generation sequencing platform.
May S; Adamska E; Tang J
J Clin Virol; 2020 Jun; 127():104376. PubMed ID: 32344322
[TBL] [Abstract][Full Text] [Related]
9. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.
Santoro MM; Fabeni L; Armenia D; Alteri C; Di Pinto D; Forbici F; Bertoli A; Di Carlo D; Gori C; Carta S; Fedele V; D'Arrigo R; Berno G; Ammassari A; Pinnetti C; Nicastri E; Latini A; Tommasi C; Boumis E; Petrosillo N; D'Offizi G; Andreoni M; Ceccherini-Silberstein F; Antinori A; Perno CF
Clin Infect Dis; 2014 Apr; 58(8):1156-64. PubMed ID: 24429430
[TBL] [Abstract][Full Text] [Related]
10. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
12. High Prevalence of HIV Low Abundance Drug-Resistant Variants in a Treatment-Naive Population in North Rift Kenya.
Cheriro W; Kiptoo M; Kikuvi G; Mining S; Emonyi W; Songok E
AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1274-7. PubMed ID: 26414430
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
Raymond S; Nicot F; Carcenac R; Lefebvre C; Jeanne N; Saune K; Delobel P; Izopet J
J Antimicrob Chemother; 2018 May; 73(5):1152-1157. PubMed ID: 29444253
[TBL] [Abstract][Full Text] [Related]
14. Subtype-independent near full-length HIV-1 genome sequencing and assembly to be used in large molecular epidemiological studies and clinical management.
Grossmann S; Nowak P; Neogi U
J Int AIDS Soc; 2015; 18(1):20035. PubMed ID: 26115688
[TBL] [Abstract][Full Text] [Related]
15. Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance.
Novitsky V; Nyandiko W; Vreeman R; DeLong AK; Manne A; Scanlon M; Ngeresa A; Aluoch J; Sang F; Ashimosi C; Jepkemboi E; Orido M; Hogan JW; Kantor R;
Microbiol Spectr; 2022 Dec; 10(6):e0345422. PubMed ID: 36445146
[TBL] [Abstract][Full Text] [Related]
16. MiDRM
Aralaguppe SG; Ambikan AT; Ashokkumar M; Kumar MM; Hanna LE; Amogne W; Sönnerborg A; Neogi U
Viruses; 2019 Aug; 11(9):. PubMed ID: 31480341
[TBL] [Abstract][Full Text] [Related]
17. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing.
Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Abdurahman S; Marrone G; Neogi U; Tegbaru B; Sönnerborg A
Sci Rep; 2018 May; 8(1):7556. PubMed ID: 29765082
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 genotypic drug resistance testing: digging deep, reaching wide?
Van Laethem K; Theys K; Vandamme AM
Curr Opin Virol; 2015 Oct; 14():16-23. PubMed ID: 26114581
[TBL] [Abstract][Full Text] [Related]
20. Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR.
Ekici H; Amogne W; Aderaye G; Lindquist L; Sönnerborg A; Abdurahman S
PLoS One; 2014; 9(10):e111042. PubMed ID: 25333961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
